SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors.

Hammel P, Smith D, Afchain P, Dominguez-Tinajero S, Seitz JF, Lievre A, Van Cutsem E, Assenat E, Di Fiore F, Peeters M, Sobhani I, Raymond E and 4 more

Show all authors

Charton E, Vernerey D, De Mestier L, Lombard-Bohas C

Therapeutic advances in medical oncology19 Nov 2024Cited by 1 (Europe PMC)

PMID39563716PMCIDPMC11574894DOI10.1177/17588359241290140PepBankPUB-39563716

Read at source PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In progressive midgut NET patients receiving lanreotide with placebo, median PFS was 11.47 months (95% CI 5.4-15.3).
In plain wordsIn progressive midgut NET patients receiving lanreotide with placebo, median time without progression was 11.47 months.
Peptide
Lanreotide
Outcome
Not applicableProgression-free survival in lanreotide-only arm
Study
n = 22
Analysis
Primary
Outcome group
Tumor growth · Cancer
Studied dose
120 mg every 28 daysAs given in this study (human).
Measurements
Median PFS
11.47 months
lanreotide plus placebo arm
95% CI of median PFS
5.4 to 15.3 months
lanreotide plus placebo arm
Source sentences
Summary
The median PFS was 9.84 months (95% CI 6.8-23.3) with sunitinib and 11.47 months (95% CI 5.4-15.3) with placebo (hazard ratio (HR) = 0.80, 95% CI 0.41-1.56, p = 0.51).
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase II trial, patients with a nonresectable grade 1 or 2 midgut progressive NET and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned 1:1 to receive 37.5 mg sunitinib or a placebo, combined with 120 mg lanreotide autogel every 28 days.
Summary · context
Between January 2013 and December 2016, 44 patients were enrolled and received sunitinib (n = 22) or placebo (n = 22).
Report a problemFND-3956371601
02HumanNon-randomized trialEfficacy outcome
In progressive midgut NET patients receiving lanreotide with placebo, the objective response rate was 0.0%.
In plain wordsIn progressive midgut NET patients receiving lanreotide with placebo, the tumor response rate was 0.0%.
Peptide
Lanreotide
Outcome
Not applicableObjective response in lanreotide-only arm
Study
n = 22
Outcome group
Tumor growth · Cancer
Studied dose
120 mg every 28 daysAs given in this study (human).
Measurements
Objective response rate
0%
lanreotide plus placebo arm
Source sentences
Summary
The objective response rate was 9.1% with sunitinib and 0.0% with placebo, and 19 patients (86.4%) had stable disease.
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase II trial, patients with a nonresectable grade 1 or 2 midgut progressive NET and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned 1:1 to receive 37.5 mg sunitinib or a placebo, combined with 120 mg lanreotide autogel every 28 days.
Summary · context
Between January 2013 and December 2016, 44 patients were enrolled and received sunitinib (n = 22) or placebo (n = 22).
Report a problemFND-3956371602
03HumanNon-randomized trialSafety outcome
In progressive midgut NET patients receiving lanreotide with placebo, 50.0% had at least one grade ⩾3 adverse event.
In plain wordsIn progressive midgut NET patients receiving lanreotide with placebo, 50.0% had at least one grade ⩾3 adverse event.
Peptide
Lanreotide
Outcome
Not applicableGrade three or higher adverse events in lanreotide-only arm
Study
n = 22
Outcome group
Adverse events · Whole body
Studied dose
120 mg every 28 daysAs given in this study (human).
Measurements
Patients with grade >=3 adverse event
50%
lanreotide plus placebo arm
Source sentences
Summary
Twenty-seven patients (61.4%) had at least one adverse event grade ⩾3 (sunitinib: 72.7%, placebo: 50.0%), with only one patient grade 4 for hypertension and vomiting.
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase II trial, patients with a nonresectable grade 1 or 2 midgut progressive NET and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned 1:1 to receive 37.5 mg sunitinib or a placebo, combined with 120 mg lanreotide autogel every 28 days.
Summary · context
Between January 2013 and December 2016, 44 patients were enrolled and received sunitinib (n = 22) or placebo (n = 22).
Report a problemFND-3956371603
04HumanNon-randomized trialSafety outcome
In progressive midgut NET patients receiving lanreotide with placebo, 6 deaths unrelated to treatment occurred.
In plain wordsIn progressive midgut NET patients receiving lanreotide with placebo, 6 deaths unrelated to treatment occurred.
Peptide
Lanreotide
Outcome
Not applicableDeaths unrelated to treatment in lanreotide-only arm
Study
n = 22
Outcome group
Mortality · Cancer
Studied dose
120 mg every 28 daysAs given in this study (human).
Measurements
Deaths non-related to treatment
6 deaths
lanreotide plus placebo arm
Source sentences
Summary
Eleven deaths non-related to treatment occurred (sunitinib arm: n = 5, placebo arm: n = 6).
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase II trial, patients with a nonresectable grade 1 or 2 midgut progressive NET and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned 1:1 to receive 37.5 mg sunitinib or a placebo, combined with 120 mg lanreotide autogel every 28 days.
Summary · context
Between January 2013 and December 2016, 44 patients were enrolled and received sunitinib (n = 22) or placebo (n = 22).
Report a problemFND-3956371604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.